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The intraerythrocytic malaria parasite, Plasmodium falciparum, maintains a low cytosolic Naþ concen-
tration and the plasma membrane P-type cation translocating ATPase ‘PfATP4’ has been implicated as
playing a key role in this process. PfATP4 has been the subject of signiﬁcant attention in recent years as
mutations in this protein confer resistance to a growing number of new antimalarial compounds,
including the spiroindolones, the pyrazoles, the dihydroisoquinolones, and a number of the antimalarial
agents in the Medicines for Malaria Venture's ‘Malaria Box’. On exposure of parasites to these compounds
there is a rapid disruption of cytosolic Naþ. Whether, and if so how, such chemically distinct compounds
interact with PfATP4, and how such interactions lead to parasite death, is not yet clear. The fact that
multiple different chemical classes have converged upon PfATP4 highlights its signiﬁcance as a potential
target for new generation antimalarial agents. A spiroindolone (KAE609, now known as cipargamin) has
progressed through Phase I and IIa clinical trials with favourable results. In this review we consider the
physiological role of PfATP4, summarise the current repertoire of antimalarial compounds for which
PfATP4 is implicated in their mechanism of action, and provide an outlook on translation from target
identiﬁcation in the laboratory to patient treatment in the ﬁeld.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Malaria is a serious global health problem. In the most recent
2014 World Malaria Report it was estimated that 3.2 billion people
are at risk of infection, with some 584,000 deaths in 2013 (World
Health Organization, 2014). In the absence of a vaccine, malaria
control relies primarily on chemotherapy and vector control using
insecticide-treated mosquito nets. Malaria parasites, including the
deadly Plasmodium falciparum, have developed some degree of
resistance to all of the antimalarial drugs currently in use. Recent
reports of reduced in vivo susceptibility to the ﬁrst-line treatment
artesunate (Ashley et al., 2014) give cause for increasing concern,
and underpin an urgent need to develop newantimalarial therapies.
Although target-based drug discovery approaches are still being
pursued (Coteron et al., 2011; Chatterjee and Yeung, 2012), recent
efforts to identify new candidate antimalarials have focussed on
high-throughput ‘phenotypic’ screening of large chemical libraries
for compounds that kill the parasite in ‘whole-cell’ assays (Plouffe(Infectious Diseases), Wash-
63110, USA.
illman).
Ltd on behalf of Australian Society fet al., 2008; Gamo et al., 2010; Guiguemde et al., 2010). Deter-
mining the target and the mechanism of action for compounds
identiﬁed in such screens is challenging. One approach that has
been used successfully involves the generation of resistant para-
sites by prolonged exposure of parasites to the compound of in-
terest, then recovery and analysis of the genomic DNA of resistant
parasites to identify resistance-associated mutations. Using this
technique, multiple recent studies have implicated the Plasmodium
falciparum P-type ATPase 4, PfATP4 (PFL0590c; PF3D7_1211900), in
resistance to, and hence in the action of, a diverse range of new
antimalarials (Rottmann et al., 2010; Flannery et al., 2014; Jimenez-
Diaz et al., 2014; Lehane et al., 2014; Vaidya et al., 2014).2. Naþ regulation in P. falciparum-infected erythrocytes
The maintenance of a low cytosolic Naþ concentration ([Naþ]cyt)
is a fundamental characteristic of all cells. Cells maintain a low
[Naþ]cyt by limiting Naþ inﬂux, by sequestering Naþ and through
the action of Naþ efﬂux transporters. Human erythrocytes maintain
a low [Naþ]cyt through the extrusion of Naþ via a well-
characterised, ouabain-sensitive P-type Naþ/Kþ-ATPase. Thus,
upon parasite invasion of a host erythrocyte, the Plasmodiumor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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from the high-[Naþ]/low-[Kþ] environment of the blood plasma, to
the low-[Naþ]/high-[Kþ] environment of the host cell cytosol (Lee
et al., 1988). Some 12e18 h after invasion (i.e. in the ‘ring’ stage)
there is a signiﬁcant increase in the permeability of the erythrocyte
membrane to a wide range of low molecular weight solutes,
including Naþ and Kþ (Ginsburg et al., 1985; Kirk et al., 1994;
Staines et al., 2001). Naþ enters the infected erythrocyte, down its
inward concentration gradient, via parasite-induced “New Perme-
ability Pathways”. The increased inﬂux of Naþ, and the consequent
increase in [Naþ] in the erythrocyte cytosol, stimulates the Naþ/Kþ-
ATPase; its activity increases more than twofold in an effort to
maintain a low erythrocytic [Naþ] (Staines et al., 2001). However
this is insufﬁcient to counter the increased inﬂux of Naþ. Further-
more, as the intraerythrocytic parasite matures, the Naþ/Kþ-ATPase
activity subsequently decreases (Staines et al., 2001), perhaps as a
result of a reduction in the Mg2þ/ATP ratio in the erythrocyte
cytosol, a key determinant of Naþ/Kþ-ATPase activity (Atamna and
Ginsburg, 1997; Mauritz et al., 2009). The overall result of these
changes is that the erythrocyte [Naþ]cyt progressively increases,
eventually reaching a concentration similar to that in the extra-
erythrocytic plasma (Lee et al., 1988; Lew et al., 2003; Pillai et al.,
2013). Under normal physiological conditions this is around
130 mM; in patients with malaria it may fall below this as malaria-
associated hyponatremia is common (English et al., 1996; Hanson
et al., 2009; van Wolfswinkel et al., 2010).
The intraerythrocytic parasite is enclosed within a para-
sitophorous vacuolemembranewhich, at themature, metabolically
active, trophozoite stage, is thought to be freely permeable to low
molecular weight solutes (including inorganic ions) due to the
presence in this membrane of high-conductance broad-selectivity
channels (Desai et al., 1993; Desai and Rosenberg, 1997). The [Naþ]
in the parasitophorous vacuole is therefore expected to be similar
to that in the erythrocyte cytosol.
Despite a high-extraparasitic [Naþ] in the host erythrocyte
cytosol (and, presumably, the parasitophorous vacuole space), the
parasite itself maintains a low [Naþ]cyt (Ginsburg et al., 1986; Lee
et al., 1988; Wunsch et al., 1998; Mauritz et al., 2011; Spillman
et al., 2013a; Flannery et al., 2014; Jimenez-Diaz et al., 2014; Vai-
dya et al., 2014). There is therefore an inward [Naþ] gradient across
the plasma membrane of the mature parasite. This combines with
the parasite's high inwardly-negative membrane potential
(approximately 95 mV (Allen and Kirk, 2004)) to constitute a
large inwardly directed Naþ electrochemical gradient. The Naþ
electrochemical gradient provides a source of energy for the active
uptake by the parasite of the essential nutrient inorganic phos-
phate, which is transported across the parasite plasma membrane
via a Naþ/phosphate symporter (Saliba et al., 2006). Initial experi-
ments suggested that maintenance of an inwardly directed Naþ
gradient was essential for parasite growth (Brand et al., 2003).
More recently it has been shown that parasites can be cultured in a
low-Naþ medium, under which conditions the increase in [Naþ] in
the host erythrocyte cytosol is prevented (Pillai et al., 2013). This
argues against an essential role for the increased erythrocyte [Naþ]
under the particular experimental conditions tested. However, as
has been pointed out (Kirk and Lehane, 2014), for parasitised
erythrocytes in low Naþ medium there is still likely to be both an
inward [Naþ] gradient and an inwardly negative membrane po-
tential, and therefore an inward Naþ electrochemical gradient. It
therefore remains untested and unknown to what extent this
gradient is important for parasite development.
The parasite's ability to maintain a large inwardly directed Naþ
gradient (even in the presence of supra-physiological extracellular
[Naþ] (Spillman et al., 2013a)), is consistent with the parasite
having an active Naþ extrusion mechanism. The presence of such amechanism was conﬁrmed by the demonstration of the ability of
the parasite to extrude Naþ from parasites pre-loaded with Naþ,
against a steep inward Naþ gradient (Spillman et al., 2013a). The
maintenance of a low cytosolic [Naþ] is disrupted by the P-type
cation-ATPase inhibitor orthovanadate and it has been postulated
that the active extrusion of Naþ from the parasite is via PfATP4
(Spillman et al., 2013a), one of seven putative cation-transporting
P-type ATPases encoded by P. falciparum (Martin et al., 2005,
2009a). PfATP4 is expressed at all stages of the asexual erythro-
cytic cycle (Rottmann et al., 2010), and is localised to the parasite
plasma membrane (Dyer et al., 1996; Rottmann et al., 2010).
PfATP4 was initially annotated as a Ca2þ-transporting ATPase,
on the basis of sequence similarities to known Ca2þ pumps
(Trottein and Cowman, 1995, Trottein et al., 1995, Dyer et al., 1996;
Krishna et al., 2001). Initial experiments involving the heterologous
expression of PfATP4 in Xenopus laevis oocyte membranes gave
results consistent with PfATP4 having a Ca2þ-dependent ATPase
activity (Krishna et al., 2001); however these results were not
replicated in a subsequent study (Rottmann et al., 2010) and, in any
case, a Ca2þ transport function has not been demonstrated directly.
Ca2þ-ATPases are closely related to another class of P-type Naþ-
ATPases, the type IID ENA-ATPases (exitus natrus, translating to exit
of salt; (reviewed in Rodriguez-Navarro and Benito, 2010)), which
efﬂux Naþ from cells of lower eukaryotes including fungi, bryo-
phytes and several protozoan parasites (including Trypanosoma
(Caruso-Neves et al., 1999; Iizumi et al., 2006), Leishmania (Stiles
et al., 2003; de Almeida-Amaral et al., 2008) and Entamoeba (De
Souza et al., 2007)).
The observation that the presence of extracellular Naþ imposes
a signiﬁcant ‘acid load’ has led to the hypothesis that PfATP4-
associated Naþ efﬂux is coupled to the inﬂux of Hþ equivalents
(Spillman et al., 2013b, 2013a). A Naþ/Hþ countertransport mech-
anism has been proposed for members of the ENA-ATPase family
(Rodriguez-Navarro and Benito, 2010) and cation countertransport
is a feature of many other P-type ATPases (Niggli and Sigel, 2008).
The acid load arising from the inﬂux of Hþ equivalents is countered
by a plasma membrane V-type Hþ-ATPase (Saliba and Kirk, 1999;
Hayashi et al., 2000). PfATP4 is thus proposed to be (at least to a
signiﬁcant extent) responsible for the “abundant proton pumping”
conundrum (i.e. the presence of a powerful plasma membrane Hþ-
ATPase, without there being an obvious metabolic requirement for
it) posited by Ginsburg (2002). Although not discussed by
Rottmann et al. (2010), parasites with mutations in pfatp4 were
found to show a signiﬁcant (albeit small, almost two-fold) cross
resistance to concanamycin A (an inhibitor of V-type Hþ-ATPases;
(Rottmann et al., 2010)). One possible explanation for any such
cross-resistance is that the mutant PfATP4 has reduced activity
relative to the wild type protein, with the result that there is
reduced Hþ countertransport in the PfATP4 mutant line and hence
a reduced requirement for Hþ-pumping by the V-type Hþ-ATPase.
Fig. 1 shows a schematic of the proposed mechanisms of Naþ
regulation in malaria parasite infected erythrocytes.
3. Multiple inhibitors show an association with PfATP4
PfATP4 has been implicated in the mechanism of action of a
chemically diverse array of antimalarial drug candidates, many of
which have been shown to disrupt parasite Naþ regulation. The
chemical structures of representatives of the different chemical
classes identiﬁed to date are shown in Fig. 2, and relevant data for
parasite EC50 values (i.e. the concentration of a drug that gives half-
maximal inhibition of parasite growth) and PfATP4 mutations are
summarised in Table 1 and Fig. 3. Prolonged culturing of parasites
in the presence of these compounds gives rise to parasites showing
some degree of resistance, associated in each case with mutations
Fig. 1. The putative role of PfATP4 in Naþ homeostasis in the malaria parasite,
P. falciparum. PfATP4 is indicated by the circle labelled ‘P’ and the V-type Hþ-ATPase is
indicated by the circle labelled ‘V’. The parasite resides within the parasitophorous
vacuole, the membrane of which is thought to be freely permeable to low molecular
weight solutes, including inorganic ions such as Naþ. The Naþ concentration within the
parasitophorous vacuole is therefore likely to be similar to that in the erythrocyte
cytosol. A) PfATP4 is postulated to function as a Naþ-ATPase, actively extruding Naþ
from the intraerythrocytic parasite, countering the inward leak of Naþ (via unknown
pathways) and maintaining a low [Naþ]cyt (approximately 10 mM). The PfATP4-
mediated efﬂux of Naþ is proposed to be accompanied by an inﬂux of Hþ ions and
this constitutes a signiﬁcant acid-load on the parasite. Hþ ions entering the parasite via
the putative Naþ-ATPase are extruded by the plasma membrane V-type Hþ-ATPase,
with the parasite pHcyt maintained at approximately 7.3. B) Inhibition of PfATP4 results
in an increase in [Naþ]cyt as Naþmoves into the cell, down its electrochemical gradient,
via the Naþ leak pathways. There is a concomitant increase in pHcyt, attributed to the
lifting of the PfATP4-mediated acid load.
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types should have converged on PfATP4 is unclear; however the
convergence potentially reﬂects the critical biological role of Naþ
regulation, and/or limitations in the number of accessible drug
targets in Plasmodium, noting that the whole-cell screening
approach is limited in discovering targets that are essential,
inhibitable and accessible in in vitro culture.
3.1. Spiroindolones
An initial spiroazepineindole lead compound was identiﬁed in a
high-throughput screen of approximately 12,000 compounds for
the ability to inhibit the growth of asexual blood-stage malaria
parasites. The screen was carried out at the Genomics Institute of
the Novartis Research Foundation (GNF) (Plouffe et al., 2008).
Several spiroindolone (a term describing spiroazepineindoles and
spirotetrahydro-b-carbolines) derivatives were synthesised (Yeung
et al., 2010), with the most active compound, NITD609 (renamed
KAE609 and now to be rebranded as cipargamin; Fig. 2A), killing
culture-adapted and ﬁeld isolates of P. falciparum and Plasmodium
vivax with an EC50 of <10 nM (Rottmann et al., 2010) (Table 1).
KAE609 also inhibits gametocyte development (in an in vitro
growth assay) and oocyst development in mosquitoes (van Pelt-
Koops et al., 2012). KAE609 displayed no signiﬁcant cytotoxicity
against mammalian cells, and a single dose (100 mg/kg) was shown
to completely cure a mouse Plasmodium berghei infection
(Rottmann et al., 2010). The early promise of KAE609 in both in vitro
and in vivo assays, led to it being awarded theMedicines for Malaria
Venture Project of the Year in 2009 (http://mmv.org/research-
development/project-year-award/project-year-award-2009; Lastaccessed May, 2015).
Parasites grown in incrementally increasing concentrations of
KAE609 (or another spiroindolone, NITD678) developed resistance
to the compounds, and a high-density tiling array using genomic
DNA from these parasites revealed that all mutant parasite lines
had at least one non-synonymous mutation in pfatp4 (Rottmann
et al., 2010) (Table 1). The EC50 values for inhibition of parasite
growth increased 7- to 24-fold in the spiroindolone-resistant lines
(Rottmann et al., 2010) (Table 1). Most (6/8) of the associated amino
acid changes reside in the predicted transmembrane helices of
PfATP4 (Rottmann et al., 2010) (Fig. 3A). The ability of these mu-
tations to confer resistance to KAE609 was investigated by over-
expressing mutant PfATP4 in wild-type parasites (Rottmann et al.,
2010). Parasites overexpressing mutant PfATP4 showed increased
EC50 values for parasite killing by KAE609, relative to the EC50
values seen for parasites overexpressing the wild-type form of the
protein (Table 1). Resistant parasites generated against KAE609
were cross-resistant to other spiroindolones (Rottmann et al., 2010;
Spillman et al., 2013a).
For two of the active spiroindolone derivatives (NITD246 and
NITD139) it was shown that addition of the spiroindolones to
parasites (functionally isolated from their host erythrocyte using
saponin) resulted in an immediate-onset, time-dependent increase
in [Naþ]cyt (Spillman et al., 2013a), consistent with the compounds
inhibiting active extrusion of Naþ. At the same time NITD246
caused a cytosolic alkalinisation, increasing the transmembrane Hþ
gradient (Spillman et al., 2013a). This alkalinisation was attributed
to a lifting of the acid load associated with the proposed Naþ/Hþ
countertransport mechanism for PfATP4 (Spillman et al., 2013b)
(see Section 2; Fig. 1). Inhibition of the plasma membrane V-type
Hþ ATPase, by concanamycin A, causes a signiﬁcant cytosolic
acidiﬁcation (Saliba and Kirk, 1999). This concanamycin-A induced
acidiﬁcation was signiﬁcantly reduced in the presence of NITD246,
again attributed to inhibition of PfATP4-mediated acid loading by
the spiroindolone (Spillman et al., 2013b). NITD246 did not affect
the resting cytosolic [Ca2þ], and neither NITD246 or NITD139
affected cellular ATP levels within the timescale of the experiments,
arguing against general ion disruption or cell energy deﬁcit as the
mechanism of action (Spillman et al., 2013a). Both a KAE609-
resistant selected parasite line and a transgenic parasite line over-
expressing mutant PfATP4 showed signiﬁcantly increased resting
[Naþ]cyt levels, reduced Naþ efﬂux rates, and an increased sensi-
tivity to the growth-inhibitory effects of supra-physiological
extracellular Naþ, compared to their wild type counterparts
(Spillman et al., 2013a).
PfATP4 mutations conferring spiroindolone-resistance occur in
regions of the protein that are highly conserved between malaria
parasite species, with an evolutionary analysis concluding that
these mutations play a role in drug resistance and are not present
due to genetic drift (Gardner et al., 2011). Distinguishing resistance-
associated mutations from non-adaptive polymorphisms will
contribute to effective surveillance if the spiroindolones progress to
the ﬁeld. KAE609 was the “ﬁrst molecule with a novel mechanism
of action to successfully complete Phase IIa studies for malaria in
the last 20 years” (http://www.mmv.org/research-development/
project-portfolio/kae609; Accessed May, 2015) and is making
rapid progress through the drug development pipeline. Further
details on the clinical trials for KAE609 (i.e. cipargamin) are
included in Section 6.
3.2. Antimalarial compounds from the Malaria Box
The Medicines for Malaria Venture's Malaria Box is a diverse set
of 400 compounds, selected from ‘hits’ identiﬁed in various high-
throughput phenotypic screens of large chemical libraries for
Fig. 2. Representative chemical structures of multiple chemotype classes showing an association with PfATP4. A) KAE609/cipargamin, a spiroindolone, B) MMV007275 and C)
MMV0011567, two carboxamides from the MMV Malaria box, D) GNF-Pf4492, an aminopyrazole, E) 21A092, a pyrazoleamide, and F) (þ)-SJ733, a dihydroisoquinolone.
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whole-cell assays (see detailed compilation information in
Spangenberg et al., 2013). In a study by Lehane et al. (2014) all 400
compounds were screened for their ability to disrupt parasite Naþ
regulation. Remarkably, 28 of the 400 compounds (i.e. 7%) dis-
rupted Naþ homeostasis at a test concentration of 1 mM (Lehane
et al., 2014). All 28 compounds also disrupted parasite pH regula-
tion in the same manner as the spiroindolones (causing an increase
in pHi, as well as reduced acidiﬁcation in response to inhibition of
the plasma membrane V-type Hþ ATPase). Along with three
spiroindolone-like compounds, multiple new potential PfATP4-
targeting chemotypes were identiﬁed (Lehane et al., 2014).
Twenty two of the 28 compounds contained a carboxamide func-
tional group. Six compounds, representing multiple chemotypes
(MMV011567, MMV665949, MMV007275, MMV006656,
MMV006764, MMV665826), were tested for cross-resistance
against the spiroindolone-resistant line, NITD609-RDd2-clone#2
(the line generated in Rottmann et al., 2010), and for all six of these
Malaria Box compounds, the spiroindolone-resistant line showed
signiﬁcant resistance compared to the parental line (Lehane et al.,
2014). For two of these compounds (MMV011567 and
MMV007275; Fig. 2B, C) resistant parasiteswere generated by long-
term culture of parasites in the presence of sub-lethal concentra-
tions of the compound. For both compounds, the EC50 values for
inhibition of parasite growth increased approximately 5-fold in the
compound-resistant lines (Lehane et al., 2014). Whole genome
sequencing was not undertaken, though Sanger sequencing of the
pfatp4 locus revealed that for both compounds there were muta-
tions at single, distinct positions in pfatp4 (Lehane et al., 2014;
Table 1; Fig. 3B). These mutations were different to the mutations
identiﬁed in the spiroindolone-resistant lines.
In another study, an undisclosed subset of the Malaria Box
compounds was screened against parasite lines resistant to anotherPfATP4 interacting compound, the pyrazole-urea GNF-Pf4492
(Flannery et al., 2014; see Section 3.3 below). For two compounds,
MMV666124 and MMV020660 (both identiﬁed as causing disrup-
tion of ion homeostasis in the Lehane et al. study (2014)), signiﬁ-
cant cross resistance was observed (Flannery et al., 2014).
3.3. Pyrazoles
The pyrazole-ureas were ﬁrst identiﬁed in the GNF high
throughput screen (the same screen identifying the spiroindolone
chemotype; Plouffe et al., 2008). They were identiﬁed indepen-
dently in an in silico screen of 300,000 compounds for inhibitors of
the Plasmodium ‘myosin tail interacting protein’/myosin A interac-
tion (Kortagere et al., 2010). This interaction is thought to play a
crucial role in invasion of host cells by the parasite (Bosch et al.,
2006). However, when the compounds identiﬁed as in silico hits
were exposed to parasites, they were found to kill the parasite
throughout the entire life cycle, not just during the invasion process
(Kortagere et al., 2010). This is consistent with the pyrazole-urea
compounds having one or more additional/alternative targets, or
with the aforementioned interaction playing a role additional to
that in invasion.
3.3.1. Pyrazole-ureas (aminopyrazoles)
The pyrazole-urea GNF-Pf4492 (Fig. 2D) inhibits the growth of
asexual P. falciparum blood-stage, parasites with an EC50 value of
184 nM (Flannery et al., 2014). Like KAE609, GNF-Pf4492 also in-
hibits oocyst formation in the mosquito midgut, demonstrating its
transmission blocking potential (Flannery et al., 2014). Parasites
resistant to GNF-Pf4492 were generated by long-term exposure of
parasites to sub-lethal concentrations of the compound, and three
independently-generated resistant lines were subjected to whole
genome sequencing (Flannery et al., 2014). The EC50 values for
Table 1
Summary of antimalarial compounds for which mutations in PfATP4 have been associated with resistance. The parent parasite strain is the Dd2 line, and transgenic parasites all have the Dd2 parent background, unless indicated
otherwise. Additional mutations in genes other than PfATP4 are included (in italics, after the relevant PfATP4 mutations). EC50 values were determined in asexual in vitro culture assays. Further information, particularly with
regard to EC50 values for multiple compound derivatives and cross resistance EC50 values between the different compounds are available from the original publications referred to. NR ¼ not reported.
Compound class Derivative EC50 against parent
parasites (± SEM)
PfATP4 mutations identiﬁed after resistance selection,
and EC50 against mutant parasites (± SEM)
Relevant transgenic parasites generated and EC50 against
transgenic parasites (± SEM)
Reference
Spiroindolones KAE609
(NITD609)
0.44 ± 0.03 nM I398F, P990R
(NITD609-RDd2 clone#1) Also D1247Y
10.9 ± 1.6 nM Dd2attB wild-type
(EF1a promoter, overexpression)
0.92 ± 0.03 nM (Rottmann et al., 2010)
T418N, P990R
(NITD609-RDd2 clone#2)
3.7 ± 1.0 nM Dd2attB D1247Y
(EF1a promoter, overexpression)
1.57 ± 0.14 nM
D1247Y
(NITD609-RDd2 clone#3)
3.2 ± 0.6 nM Dd2attB I398F/P990R
(EF1a promoter, overexpression)
1.89 ± 0.06 nM
Dd2attB D1247Y
(CAM promoter, overexpression)
3.90 ± 0.65 nM
Dd2attB I398F/P990R
(CAM promoter, overexpression)
4.25 ± 0.54 nM
NITD678 21.9 ± 1.2 nM G223R
(NITD678-RDd2 clone#1)
193 ± 39 nM
A184S, P990R
(NITD678-RDd2 clone#2) and I119S
(ADP/ATP transporter) (Bopp et al., 2013)
162 ± 16 nM
I203M, I263V
(NITD678-RDd2 clone#3)
241 ± 32 nM
Malaria Box
compounds
MMV011567 0.34 ± 0.05 mM Q172K
(MMV011567-pressured culture 1)
1.63 ± 0.22 mM (Lehane et al., 2014)
A353E*
(MMV011567-pressured culture 2)
*This mutation was originally reported
as A353Q (Lehane et al., 2014)
but was corrected in a subsequent
corrigendum to A353E.
1.89 ± 0.24 mM
MMV007275 0.23 ± 0.02 mM Q172H
(MMV007275-pressured culture 1)
1.10 ± 0.18 mM
(continued on next page)
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Table 1 (continued )
Compound class Derivative EC50 against parent
parasites (± SEM)
PfATP4 mutations identiﬁed after resistance selection,
and EC50 against mutant parasites (± SEM)
Relevant transgenic parasites generated and EC50 against
transgenic parasites (± SEM)
Reference
Pyrazoles GNF-Pf4492
(a pyrazole-urea)
184.1 nM A211T
(GNF-Pf4492R-1)
1170 nM Dd2attB wild-type
(CAM promoter, overexpression)
~1.5 fold shift (EC50 NR) (Flannery et al., 2014)
I203L, P990R
(GNF-Pf4492R-2)
811.0 nM Dd2attB A211T
(CAM promoter, overexpression)
~4.4 fold shift (EC50 NR)
A187V
(GNF-Pf4492R-3) and I301N
(ADP/ATP transporter)
631.0 nM
PA21A092
(a pyrazole-amide)
12.9 ± 2.0 nM V178I
(Dd2-R-1, Dd2-R21-2 and Dd2-R21-3)
and T392A (PfCDPK5), D133Y (DNA
polymerase alpha; PF3D7_0411900),
N142K (DEAD/DEAH box ATP-dependent
RNA helicase; PF3D7_0630900),
K465E (thioredoxin-like associated
protein 2; PF3D7_1034300)
133 ± 8 nM Dd2::PfCDPK5T392A
(endogenous promoter, integration)
23 ± 3 nM (Vaidya et al., 2014)
Note: resistant parasites
raised against C2-1 compoundDd2attB PfATP4wild-type
(CAM promoter, overexpression)
22 ± 9 nM
Dd2attB PfATP4V178I
(CAM promoter, overexpression)
34 ± 3 nM
Dd2::PfCDPK5T392A
(endogenous promoter, integration) þ
Dd2attB PfATP4wild-type
(CAM promoter, overexpression
from an expisome)
31 ± 4 nM
Dd2::PfCDPK5T392A
(endogenous promoter, integration) þ
Dd2attB PfATP4V178I
(CAM promoter, overexpression
from an episome)
176 ± 8 nM
Dihydroiso-
quinolones
(þ)-SJ733 20 nM
(Dd2 parent)
30 nM
(3D7 parent)
V415D
(SJ81-733) 3D7
EC50 NR P. berghei expressing PfATP4 at the
PbATP4 locus
(Jimenez-Diaz et al., 2014)
L350H
(SJ82-733) 3D7
EC50 NR
P412T
(SJ83-733) 3D7
15 mM
G358S
(DD2-SJ16-D2) Dd2
5 fold
(EC50 NR)
L928F
(DD2-SJ16-B7) Dd2
3 fold
(EC50 NR)
SJ311
(structure undisclosed)
20 nM
(3D7 parent)
P437S
(P. berghei)
2 fold
(EC50 NR)
L350H
(SJ72-311) 3D7
EC50 NR
SJ247
(structure undisclosed)
50 nM
(Dd2)
P966S
(UC7-247)
W2 parent
330 nM
SJ279
(structure undisclosed)
40 nM
(Dd2)
P966T
(UC8-279)
W2 parent
90 nM
MMV772 Details/structures
undisclosed
EC50 NR
(3D7 parent)
F917L
(3D7-C9-ATP4F917L)
100 fold
(EC50 NR)
Unpublished
(http://www.mmv.
org/newsroom/news/three-
new-roads-leading-common-
pathway; Report dated
9 December, 2014; Last
accessed May, 2015) and
(Jimenez-Diaz et al., 2014)
EC50 NR
(W2 parent)
P412L
(W2-F6-ATP4P412L)
10 fold
(EC50 NR)
N
.J.Spillm
an,K
.K
irk
/
InternationalJournal
for
Parasitology:
D
rugs
and
D
rug
Resistance
5
(2015)
149
e
162
154
Fig. 3. PfATP4 homology model showing mutations observed in parasites resistant to each of the different chemotypes for which the mechanism of action has been linked to
PfATP4. The homology model of PfATP4 (using the full length sequence as input) was generated using the I-TASSER server (Zhang, 2008; Roy et al., 2010), and rendered with PyMOL
Molecular Graphics System, Version 1.7.4 Schr€odinger, LLC. The top structural analogues used were 2DQS (rabbit Ca2þ-ATPase), 2KDP (pig Naþ/Kþ-ATPase) and 2ZXE (spiny dogﬁsh
Naþ/Kþ-ATPase). The amino acids represented in red are the resistance-associated mutant residues, with the atoms in these amino acids depicted as red spheres. The predicted
approximate transmembrane region of the protein is delineated by the dashed lines. Table 1 provides a full list of the mutations. Resistance-associated mutations occur pre-
dominantly in the transmembrane helices for: A) the spiroindolones KAE609 and NITD678; B) two carboxamides from the MMV Malaria box, MMV007275 and MMV0011567 (one
of the two alternative mutations reported at position 172 e Q172K e is shown); C) an aminopyrazole, GNF-Pf4492; D) a pyrazoleamide, C2-1; E) the dihydroisoquinolones
(þ)-SJ733, SJ311, SJ247 and SJ279 (one of the two alternative mutations reported at position 966 e P966S e is shown); and F) MMV772.
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compound-resistant lines relative to the parent line (Flannery et al.,
2014). All three had mutations in pfatp4 (Flannery et al., 2014;
Table 1; Fig. 3C). One of these mutations, P990R, had been reported
in spiroindolone-resistant parasites (Rottmann et al., 2010). The
others were previously undescribed. One of the resistant lines also
had a mutation in the ﬁnal (C-terminal) amino acid of the putative
ADP/ATP transporter (PF3D7_1037300). Although the ADP/ATP
transporter was initially localised to the inner mitochondrial
membrane (Hatin et al., 1992), there is functional evidence for its
presence on the parasite plasmamembrane (Kanaani and Ginsburg,
1989; Choi and Mikkelsen, 1990; Saliba et al., 2003). What role, if
any, either a mitochondrial or plasma membrane ADP/ATP
exchanger might play in the resistance phenotype was not inves-
tigated. Mutations in the calcium-dependent protein kinase 5
(pfcdpk5; PF3D7_1337800) were reported in the pyrazole-urea
resistant parasites, although these mutations were also present in
the parent line and their functional signiﬁcance was not investi-
gated (Flannery et al., 2014).
The role of the PfATP4 mutations identiﬁed in this study were
investigated using multiple transgenic parasite lines. Parasite lines
overexpressing wild-type PfATP4 (generated in Rottmann et al.,
2010; Flannery et al., 2014) showed a modest, approximately 1.5
fold, decrease in the sensitivity to GNF-Pf4492 relative to the
relevant Dd2attB parent line (Flannery et al., 2014). When the
mutant PfATP4 was overexpressed, there was a greater decrease in
sensitivity (3.6e4.4 fold compared to the Dd2attB parent) (Flannery
et al., 2014). Two of the three GNF-Pf4492 resistant parasite lines
were cross resistant to the spiroindolones tested (KAE609, KAE678
and NITD246); however the other was found to be hypersensitiveto the spiroindolones. The mechanism of this hypersensitivity was
not investigated (Flannery et al., 2014).
Addition of GNF-Pf4492 to saponin-isolated parasites resulted
in an increase in [Naþ]cyt (Flannery et al., 2014), although the time-
frame of Naþ inﬂux was somewhat slower than that observed in
other studies (Spillman et al., 2013a; Jimenez-Diaz et al., 2014;
Lehane et al., 2014; Vaidya et al., 2014). Like the spiroindolone-
resistant parasite lines (Spillman et al., 2013a), the GNF-Pf4492
resistant lines showed reduced sensitivity to the disruption of
Naþ regulation and an increased resting [Naþ]cyt (in 2/3 lines)
(Flannery et al., 2014). These data are consistent with the involve-
ment of PfATP4 in parasite Naþ regulation.
3.3.2. Pyrazoleamides
From a different pyrazole-urea lead (one in which the bromide
group of GNF-Pf4492 is replaced with a methoxy group), several
pyrazoleamide derivatives were synthesised, with the aim of
developing compounds more potent than the pyrazole-ureas at
killing parasites (Vaidya et al., 2014). A number of these were found
to kill asexual stage P. falciparum laboratory strains with EC50 values
<10 nM, and to kill P. falciparum and P. vivax ﬁeld isolates with EC50
values <18 nM (Vaidya et al., 2014). The lead compound, PA21A092
(Fig. 2E), like the spiroindolone KAE609, also inhibited gametocyte
development, with reduced conversion of gametocytes to gametes
(Vaidya et al., 2014). In an in vivo mouse model of malaria, using
P. falciparum parasites in NOD/SCID/IL2Rgnull mice, clearance of
parasites following PA21A092 treatment (one dose per day for four
consecutive days, commencing on day-3 post-infection) was as
rapid as that seen with artesunate (Vaidya et al., 2014). The ED90
(effective dose for reduction of parasitaemia by 90%) for PA21A092
N.J. Spillman, K. Kirk / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 149e162156was 2.5 mg/kg (Vaidya et al., 2014).
To investigate the mechanism of pyrazoleamide killing,
P. falciparum lines resistant to the pyrazoleamides were generated
by exposure to a high concentration (3 EC50) of one of the pyr-
azoleamide derivatives, compound C2-1 (Vaidya et al., 2014). Three
independent resistant lines were generated, showing an approxi-
mately 20-fold increase in the EC50 value for the inhibition of
parasite growth relative to the parent line. All three showed cross-
resistance to other pyrazoleamides, consistent with a common
mechanism of action for the compounds of this class. Whole
genome sequencing revealed that all three resistant parasite lines
harboured a mutation in pfatp4 (Fig. 3D), as well as a mutation in
each of four other genes including the gene encoding PfCDPK5
(Vaidya et al., 2014).
Introduction of the T392Amutation (alone) into the endogenous
PfCDPK5 protein resulted in a slight decrease in the sensitivity of
the parasite to the pyrazoleamides (Vaidya et al., 2014). When the
PfATP4 V178I mutant (alone), was overexpressed (and compared to
a line in which the wild-type PfATP4 was overexpressed), this
resulted in a low level of pyrazoleamide resistance (Vaidya et al.,
2014). However, when the PfCDPK5 T392A and PfATP4 V178I mu-
tations were combined (with the mutation in the pfcdpk5 gene
integrated into the endogenous locus and the mutant pfatp4 gene
overexpressed episomally) a much higher degree of resistance was
achieved, consistent with both PfATP4 and PfCDPK5 playing a role
in pyrazoleamide resistance (Vaidya et al., 2014). Notably, a pyr-
azoleamide resistant parasite line (R2-1) generated by prolonged
exposure to pyrazoleamide compound C2-1 did not display sig-
niﬁcant cross resistance to KAE609. Similarly, of the transgenic
lines only the combination of the PfCDPK5 T392A and PfATP4 V178I
mutations resulted in signiﬁcant cross resistance to KAE609
(Vaidya et al., 2014).
As is seen for the spiroindolones, addition of the pyrazoleamide
PA21A050 to saponin-isolated parasites resulted in a rapid increase
of [Naþ]cyt, an increase in cytosolic pH, and no disruption of resting
cytosolic [Ca2þ] (Vaidya et al., 2014). Concomitant with an increase
in [Naþ]cyt, the pyrazoleamide treated parasites underwent
swelling, consistent with the osmotic uptake of water (Vaidya et al.,
2014). When parasites were grown in low [Naþ] media, the parent
parasites and resistant parasites generated by prolonged exposure
to a pyrazoleamide both showed reduced sensitivity to both pyr-
azoleamides and KAE609, consistent with Naþ playing a role in theFig. 4. Potential mechanisms of parasite killing following disruption of Naþ regulation by P
parasite. This may cause: A) disruption of enzyme function, B) disruption of physiological pr
host cell swelling/lysis due to the osmotic load associated with the inﬂux of Naþ. It has been
of premature schizogony and egress via a mechanism involving the kinase PfCDPK5 and/or E
that entails the display on the erythrocyte surface of phosphatidylserine (PS), cell roundingmechanism of action of both compound classes (Vaidya et al., 2014).
PfCDPK5 is essential for merozoite release in the ﬁnal stages of
schizogony (Dvorin et al., 2010), a process that is thought to involve
schizont swelling (Gruring et al., 2011). Vaidya et al. (2014) postu-
lated that PfCDPK5may regulate PfATP4 activity, perhaps serving to
inhibit its function and thus allowing an inﬂux of Naþ and water in
order to induce schizont swelling. It was proposed that the pyr-
azoleamides (and perhaps the spiroindolones as well) might trigger
prematurely some of the events associated with the egress of par-
asites from their host erythrocyte (Vaidya et al., 2014) (see Section 4
and Fig. 4).
3.4. Dihydroisoquinolones
The antimalarial dihydroisoquinolones were identiﬁed in a
high-throughput phenotypic screen of approximately 300,000
compounds conducted at St Jude Children's Research Hospital
(Guiguemde et al., 2010). The optimised dihydroisoquinolone
(þ)-SJ733 (Fig. 2F) kills asexual parasites with EC50 values of
1060 nM in in vitro growth assays. (þ)-SJ733 was faster than
artesunate at clearing P. falciparum parasites in the NOD/SCID/
IL2Rgnull mice model (one dose per day for four consecutive days,
commencing on day three post infection; ED90 of 1.9 mg/kg) and
blocked transmission of the mouse malaria parasite P. berghei from
infected mice to mosquitos (Jimenez-Diaz et al., 2014). On the basis
of its promising safety proﬁle, oral availability and preclinical
pharmacokinetic properties, (þ)-SJ733 was endorsed for clinical
development by MMV in 2013 (http://www.mmv.org/research-
development/project-portfolio/sj733; Accessed May, 2015).
To assess the mechanism of action of (þ)-SJ733, drug-resistant
parasite strains were selected, both in vitro in P. falciparum cul-
tures (with (þ)-SJ733), and in vivo in P. berghei (with the dihy-
droisoquinolone SJ311). In the dihydroisoquinolone-resistant
parasite lines, the EC50 values for parasite killing increased from
approximately 2- to 750-fold (Jimenez-Diaz et al., 2014). Whole
genome sequencing was performed for six independent
P. falciparum selections, and in all cases mutations in pfatp4 were
observed (Jimenez-Diaz et al., 2014; Fig. 3E). Sanger sequencing at
the pfatp4 locus was performed for an additional two independent
P. falciparum selections and the P. berghei selection, and again
mutations were found in pfatp4 and pbatp4, respectively (Jimenez-
Diaz et al., 2014). The (þ)-SJ733-resistant parasite lines were cross-fATP4-associated antimalarials. PfATP4 inhibition results in a net inﬂux of Naþ into the
ocesses that are dependent on the Naþ electrochemical gradient, and/or C) parasite and
proposed that parasite and/or host cell swelling might be associated with: D) induction
) activation of eryptosis (erythrocyte suicide pathway) in the host cell via a mechanism
and enhanced clearance in vivo.
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cross-resistant to the spiroindolones KAE246 and NITD138
(Jimenez-Diaz et al., 2014). For two mutant strains (drug-selected
lines with PfATP4 mutations L350H and P966T) their ﬁtness,
compared to wild-type parasites, was tested in competition assays.
Wild-type and mutant parasites were mixed in equal proportions
(i.e. a wild-type:mutant parasite ratio of 1) and the mixed cultures
were grown in the absence of drug pressure. After 20e30 days
>90% of the parasites were wild type (a wild-type:mutant parasite
ratio >10), indicating that the mutant parasites had a signiﬁcantly
slower growth rate (i.e. ﬁtness) relative to their wild-type coun-
terparts (Jimenez-Diaz et al., 2014). The mutant parasites (with
PfATP4 mutation L350H) were shown to have a higher resting
[Naþ]cyt and it was suggested that this may contribute to the
observed ﬁtness cost (Jimenez-Diaz et al., 2014).
As for the other PfATP4-associated antimalarials, addition of
(þ)-SJ733 to isolated parasites caused a rapid increase in [Naþ]cyt
and a rapid alkalinisation of cytosolic pH, consistent with inhibition
of PfATP4 activity (Jimenez-Diaz et al., 2014). A (þ)-SJ733-resistant
parasite (L350H) showed reduced sensitivity to Naþ disruption by
(þ)-SJ733 (Jimenez-Diaz et al., 2014).
In multiple in vivo mouse malaria models, (þ)-SJ733 treatment
resulted in a rapid clearance of parasites (estimated to be four times
faster than in vitro killing) (Jimenez-Diaz et al., 2014). Treatment
with (þ)-SJ733, or KAE246, led to a rapid exposure of phosphati-
dylserine on the outer plasma membrane leaﬂet (Jimenez-Diaz
et al., 2014). This is typical of ‘eryptotic’ or senescent erythrocytes
and serves as a signal for the erythrocytes to be removed by
erythrophagocytosis or splenic clearance (Lang et al., 2010, 2012).
As was reported for the pyrazoleamides (Vaidya et al., 2014),
infected erythrocytes were shown to undergo swelling after
(þ)-SJ733 or KAE246 treatment, with the infected erythrocytes
changing from a typical biconcave disc shape to a more spherical
shape (Jimenez-Diaz et al., 2014). The authors proposed that os-
motic swelling of the parasite leads to premature eryptosis and
hence to changes in the infected erythrocyte that facilitate rapid
clearance of these cells in vivo (Jimenez-Diaz et al., 2014) (see
Section 4 and Fig. 4).
3.5. GlaxoSmithKline compounds (MMV772)
Recently, MMV has revealed the development, by Glax-
oSmithKline, of another novel chemical class that shows an asso-
ciation with PfATP4 (http://www.mmv.org/newsroom/news/three-
new-roads-leading-common-pathway; Report dated 9 December,
2014; Last accessed May, 2015). As is the case for the lead pyr-
azoleamide (21A092) and the lead dihydroisoquinolone (SJ733), the
lead compound of this chemotype (MMV772) has been “recom-
mended for full development” by the MMV External Scientiﬁc
Advisory Committee. Although the structure of these compounds
has not been revealed, it is known that MMV772-selected parasites
develop mutations in PfATP4 (Jimenez-Diaz et al., 2014) (Table 1)
that confer 10- to 100-fold resistance to MMV772, as well as cross
resistance to the dihydroisoquinolones (Jimenez-Diaz et al., 2014).
4. The nature of the association of compounds with PfATP4
The convergence on PfATP4 of so many distinct chemotypes
raises a number of key questions. How do mutations in PfATP4
confer resistance? Is PfATP4 the direct target of these compounds?
How might inhibition of PfATP4 lead to parasite killing?
One well established mechanism by which mutations in trans-
porters confer drug-resistance involves the mutant transporter
mediating the transport of the drug, away from its site of action. P-
type cation ATPases transport inorganic cations (e.g. Naþ, Kþ, Hþ,Ca2þ, Zn2þ) across membranes or catalyse the translocation of
phospholipids across membrane leaﬂets (ﬂippases) (Yatime et al.,
2009; Palmgren and Nissen, 2011). Although P-type ATPases are
themselves attractive pharmacological targets (Yatime et al., 2009),
there is not, to our knowledge, any known example of an ion
translocating P-type ATPase transporting a drug. P-type ATPases do
not share homology with knownmultidrug efﬂux transporters (e.g.
members of the ATP-binding cassette (ABC) transporter family
which can transport a multitude of metabolites and drugs). Thus,
there is no prior evidence to support the hypothesis that PfATP4
might efﬂux the various compounds of interest from the parasite.
Another possible explanation for the diversity of chemotypes
that has been associated with PfATP4 is that PfATP4 has a multi-
plicity of interacting partners that are themselves the pharmaco-
logical targets of the various compounds of interest. P-type ATPases
are known to interact with a number of cytosolic and membrane
bound proteins, and it is feasible that the activity of PfATP4 is
modulated by a range of other proteins and that compounds inter-
actingwith these proteinsmight therebyaffect PfATP4 function. The
plasma-membrane P-type Ca2þ-ATPase interacts with a large
number of proteins, including calmodulin, calcineurin A, ankyrin,
actin, and 14-3-3ε proteins (Strehler, 2013). Other examples of
proteins interacting with P-type ATPases include the interaction of
sarcolipin with the SERCA-type Ca2þ-ATPases and 14-3-3 proteins
with plant Hþ-ATPases (Bublitz et al., 2011). These interacting
partners may regulate transporter activation or function, perhaps
through allosteric regulation, by altering trafﬁcking or membrane
localisation, or byregulatingdownstreamsignalling (Strehler, 2013).
Smallmolecule inhibitionof the interactingpartnermay result in
a downregulation/inactivation of PfATP4 activity, leading to the Naþ
inﬂux observed experimentally. Mutations in pfatp4 may compen-
sate for altered interactionswith regulating partners. PfATP4maybe
regulated by kinases/phosphatases; six phosphorylation sites have
been identiﬁed (S28, S69, S86, S103, S113, Y116) (Aurrecoechea et al.,
2009; Treeck et al., 2011). Mutations in the kinase PfCDPK5 have
been associatedwith aminopyrazole resistance (Section 3.3.2) and it
is proposed that PfCDPK5 may be involved in PfATP4 regulation
(Vaidya et al., 2014), although phosphorylation of PfATP4 by
PfCDPK5 is yet to be demonstrated experimentally.
Compensatory mutations in pfatp4 may also arise if the Naþ-
pumping capacity of PfATP4 is disrupted by the various compounds
in a non-speciﬁc manner, for example if the compounds were to act
as ionophores. In the case of P. falciparum, the various small mole-
cules reviewed in Section 3 do not seem to function as proto-
nophores. Protonophores act to decrease or eliminate the
transmembrane Hþ gradient, whereas the spiroindolones
(NITD246) (Spillman et al., 2013a), the PfATP4-active Malaria Box
Compounds (Lehane et al., 2014), the pyrazoleamides (21A050)
(Vaidya et al., 2014) and the dihydroisoquinolones ((þ)-SJ733)
(Jimenez-Diaz et al., 2014) have all been shown to induce an increase
in the transmembrane Hþ gradient across the plasma membrane of
isolated parasites. It is also unlikely that the compounds act as Naþ
ionophores, as the maximal Naþ inﬂux rate observed on addition to
isolated parasites of the spiroindolones (NITD246,139,247; approx-
imately 0.1mM/s) is not signiﬁcantly different from that observed in
response to treatment of the parasites with the general P-type
ATPase inhibitor orthovanadate (Spillman et al., 2013a). This is
consistent with Naþ gradient disruption being due to P-type ATPase
inhibition, and not to an ionophoretic effect. A similar maximal Naþ
inﬂux rate, of approximately 0.08 mM/s was also measured for the
pyrazoleamide 21A050 (Vaidya et al., 2014).
The simplest explanation that would account for the data
currently available is that PfATP4 functions as a Naþ efﬂux pump,
that the PfATP4-associated compounds bind directly to PfATP4, and
that binding results in inhibition of one or more steps in the
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cation translocation (i.e. Naþ efﬂux). In this model, the time-
dependent increase in parasite Naþ observed experimentally
following the addition of ATP4-associated compounds reﬂects the
inﬂux of Naþ via (unknown) endogenous pathways. P-type ATPases
are long-established as drug targets with well-characterised in-
hibitor binding pockets (Yatime et al., 2009; Bublitz et al., 2011).
The resistance-associated mutations in PfATP4 are postulated to
reduce the afﬁnity of the interaction of the inhibitors with their
binding site(s) on the protein. The reduced sensitivity of the PfATP4
mutant parasites to the disruption of Naþ regulation (Spillman
et al., 2013a; Jimenez-Diaz et al., 2014), is consistent with this hy-
pothesis. The majority (though not all) of the resistance-associated
mutations are in a transmembrane region of the protein (which is
thereby identiﬁed as a candidate inhibitor binding site; see Fig. 3).
For at least one of the PfATP4-associated compounds, (þ)-SJ7733, in
silico docking studies have revealed how the compound might
interact with this site (Jimenez-Diaz et al., 2014). Nevertheless the
direct interaction of the small molecule inhibitors with PfATP4 has
not been demonstrated directly (see Section 7). Understanding how
the inhibitors interact with PfATP4, in both the wild-type and
mutant proteins, may help to explain why the fold-change in
sensitivity to a given compound varies between resistant parasites
carrying different mutations in PfATP4, and why for any given
resistance-conferring mutation(s) the fold-decrease in sensitivity
varies between the different chemotypes.
The disruption of Naþ (and pH) homeostasis occurs immediately
following the exposure of parasites to the PfATP4-associated com-
pound. The question of the precise mechanism(s) by which a
disruption of parasite ion homeostasis leads to parasite death, and
clearance of parasitised erythrocytes from the circulation, remains
to be elucidated. As summarised in Fig. 4, there are several possi-
bilities: (A) a high [Naþ]cyt may be detrimental to enzyme function;
(B) disruption of the Naþ electrochemical gradient might perturb
important physiological mechanisms that are reliant on this
gradient; and/or (C) the net inﬂuxof Naþ that occurs on inhibition of
the Naþ efﬂux pump may cause the parasites and perhaps, thereby,
the infected cell as a whole to swell to such an extent as to threaten
their integrity and/or trigger detrimental swelling-associated pro-
cesses in the parasite and/or erythrocyte. These three possibilities
are not mutually exclusive. All warrant further investigation.
In plants, direct Naþ toxicity (and hence the need to maintain
[Naþ]cyt at low levels) has been linked to the ability of Naþ to
interfere with the regulation of various metabolic pathways
(including glycolysis) by competing with Kþ (Munns and Tester,
2008). Increased [Naþ]cyt also inhibits cellular protein synthesis
(Carrasco and Smith, 1976), as has been reported to occur with the
spiroindolones and pyrazole-urea compounds (Rottmann et al.,
2010; Flannery et al., 2014).
The parasite uses the inwardly directed Naþ electrochemical
gradient to energise the uptake of at least one essential nutrient,
inorganic phosphate (Saliba et al., 2006), though whether this plays a
critical physiological role in vitro and, more importantly, in vivo, is
unclear. ThereareotherpotentialNaþ-coupled transportersannotated
in the parasite genome, including amino acid symporters (in the
neurotransmitter:Naþ symporter family), a sugar transporter (in the
glycosideepentosideehexuronide:cation symporter family), a multi-
antimicrobial extrusion family transporter and major facilitator su-
perfamily transporters (Martinet al., 2005).However, the localisations
and physiological roles of these proteins have not been investigated,
and nor has their dependence on Naþ been demonstrated.
Both the pyrazoleamides and dihydroisoquinolones (Jimenez-
Diaz et al., 2014; Vaidya et al., 2014) have been reported (on the
basis of light microscopy measurements) to induce swelling of
asexual blood-stage parasites, which is postulated to occur as aresult of an osmotic imbalance resulting from the net inﬂux of Naþ
(Fig. 4C). Asexual-stage parasitised erythrocytes treated with the
spiroindolone KAE609 become rounded, and have an increased
rigidity (measured using micropipette aspiration) compared to
uninfected erythrocytes (Zhang et al., in press). Gametocytes
treated with KAE609 were also reported to became swollen and
rounded (van Pelt-Koops et al., 2012), again consistent with a
disruption of osmotic stability. Many cells have the capacity to
regulate their volume in response to osmotic perturbation. The
ability of the parasite to do so is unknown.
The swelling of parasites following the addition of PfATP4-
associated compounds has been proposed to have a number of
different consequences (Fig. 4). It has been suggested that swelling
might trigger the premature lysis of the host erythrocyte by acti-
vating a merozoite release pathway, normally activated during the
last moments of schizogony (Vaidya et al., 2014). This hypothesis is
based upon the report that mutations in PfCDPK5 (a regulator of
schizont rupture (Dvorin et al., 2010)) caused an increase in the
parasite resistance to aminopyrazoles (Vaidya et al., 2014). It has
also been proposed that parasite swelling triggers eryptosis (an
endogenous erythrocyte suicide pathway) in the infected erythro-
cyte, leading to exposure of phosphatidylserine at the erythrocyte
surface, to an increase in erythrocyte rigidity and to the infected cell
becoming more spherical (Jimenez-Diaz et al., 2014). Signs of
eryptosis were also observed in a second study; however the au-
thors reported there to be no exposure of phosphatidylserine at the
erythrocyte surface (Zhang et al., in press). The end result of
eryptosis is the rapid clearance of infected erythrocytes from the
host organism. Some parasite death through lysis (inside an intact
erythrocyte) has also been observed (Jimenez-Diaz et al., 2014),
perhaps occurring as a result of osmotic water uptake. Under-
standing the precise mechanism, and downstream consequences,
of parasite swelling requires further investigation.
5. ATP4 in other Plasmodium species and other Apicomplexa
There are syntenic PfATP4 orthologues in the human malaria
parasites P. vivax and Plasmodium knowlesi, in the non-human
primate malaria parasites Plasmodium cynomolgi and Plasmodium
reichenowi, and in the rodent malaria parasites P. berghei, Plasmo-
dium chabaudi and Plasmodium yoelii (PlasmoDB (v24.0);
(Aurrecoechea et al., 2009)). P. berghei, Plasmodium vinckei and
P. chabaudi are less sensitive to (þ)-SJ733 than is P. falciparum (in
both ex vivo and in vivo experiments) (Jimenez-Diaz et al., 2014),
and it has been suggested that the differences in compound
sensitivity between the species may be due to variations in a loop
region close to the predicted (þ)-SJ733 binding site (Jimenez-Diaz
et al., 2014). There have not yet been any site directed mutagen-
esis studies to investigate the residues involved; however, in
transgenic P. berghei parasites in which the entire pbatp4 locus was
replaced with the pfatp4 locus, the sensitivity to (þ)-SJ733 was
restored almost to that observed in P. falciparum parasites (Jimenez-
Diaz et al., 2014).
Understanding the interaction of the various antimalarial agents
with P. vivax PvATP4 will be important, given the burden of P. vivax
worldwide (Baird, 2013). Initial evidence suggests that PfATP4 and
PvATP4 are similarly sensitive to spiroindolones (NITD609/cipar-
gamin), both ex vivo (Rottmann et al., 2010) and in vivo (White et al.,
2014). By contrast a pyrazoleamide (PA21A092) was signiﬁcantly
more active (ex vivo) against P. vivax than against P. falciparum
(Vaidya et al., 2014).
Naþ-ATPases are found in many pathogenic fungi and parasites
(Rodriguez-Navarro and Benito, 2010), raising the possibility that
the new PfATP4-associated antimalarial agents could be more
general anti-parasitic/anti-fungal drugs. The growth inhibitory
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should be tested in other Apicomplexa and fungi. Toxoplasma
gondii, a protozoan parasite, has a readily identiﬁable PfATP4 ho-
mologue (TgATP4, with 51% sequence identity to PfATP4 (Zhou
et al., 2014)), and a preliminary report suggests that KAE609 kills
Toxoplasma tachyzoites both in vitro, with an EC50 of approximately
1 mM, and in an in vivomousemodel (Zhou et al., 2014). Knockdown
of TgATP4 led to inhibition of tachyzoite replication, consistent with
TgATP4 function playing an important role in the T. gondii tachy-
zoite stage (Zhou et al., 2014). The identiﬁcation of novel broad
anti-parasitic/anti-fungal drugs would be a signiﬁcant break-
through in the current age of multi-drug resistant pathogens.
Additionally, as the development of KAE609 and other PfATP4-
associated compounds continue it may be possible to repurpose
the drugs to treat other infections.
6. Drug development and clinical trials
The translation of ‘bench’ experimental ﬁndings to ‘bedside’
clinical success presents a signiﬁcant challenge. Target Product
Proﬁles for antimalarial drug development have been established
(Burrows et al., 2013; Leroy et al., 2014), with fast clearance and
transmissionblockingability being thekeycharacteristics of an ideal
SERCaP (Single-Exposure Radical Cure and Prophylaxis) drug. Initial
characterisation of several of the PfATP4erelated compounds has
revealed promising clearance times as well as gametocyte blocking
abilities, and this has underpinned the decision to proceed with the
development of multiple different chemotypes (http://www.mmv.
org/newsroom/news/three-new-roads-leading-common-
pathway; Report dated 9 December, 2014; Last accessedMay, 2015).
The most advanced of the PfATP4-associated compounds
(KAE609/cipargamin) underwent Phase I clinical trials in 2010 and
2011 (Leong et al., 2014). Cipargamin was well tolerated, with mild
to moderate gastrointestinal and genitourinary adverse events
recorded (Leong et al., 2014). Data from this study, and data from
pharmacokineticepharmacodynamic preclinical investigations led
to the proposal that a daily dose of 30 mg/70 kg human would be
efﬁcacious (Lakshminarayana et al., 2014; Leong et al., 2014). Data
on the pharmacokineticepharmacodynamic properties of various
spiroindolone derivatives is being used to optimise dose and dosing
regimens, to minimise the risk of sub-optimal doses resulting in
spiroindolone resistance (Lakshminarayana et al., 2014).
In aPhase II trial, performed inThailand in2012, patients infected
with P. falciparum or P. vivax malaria were treated with 30 mg
cipargamin for three sequential days (White et al., 2014). For both
parasite species, the median parasite clearance half-life was less
than one hour, with median parasite clearance times of approxi-
mately 12 h. This is quicker than the current fastest acting antima-
larials, the artemisinins (White et al., 2014). The rapid antimalarial
activity of cipargamin bodes well for continued development of this
compound class, with further Phase II conﬁrmatory and combina-
tion clinical studies the next step in the process.
Other PfATP4-associated compounds are also beginning Phase I
trials with the dihydroisoquinolone (þ)-SJ733 scheduled for ﬁrst-
in-human trials in 2015 (http://www.mmv.org/newsroom/news/
three-new-roads-leading-common-pathway; Report dated 9
December, 2014; Last accessed May, 2015).
7. Future directions
Although results obtained to date are consistent with PfATP4
functioning as a Naþ-efﬂux ATPase, this awaits conﬁrmation by
expression of the protein in a heterologous system. Successful
heterologous expression of PfATP4 has been reported in X. laevis
oocytes (Krishna et al., 2001), and the oocyte system has beenshown to provide a useful method for the characterisation of other
Plasmodium transporters; e.g. PfENT1 (Equilibrative Nucleoside
Transporter 1; Carter et al., 2000; Parker et al., 2000), PfHT (Hexose
Transporter; Woodrow et al., 1999, Woodrow et al., 2000), PfAQP
(aquaglyceroporin; Hansen et al., 2002), PfCHA (Ca2þ/Hþ
exchanger; Rotmann et al., 2010), PfMDR1 (P-glycoprotein homo-
logue 1; Sanchez et al., 2008), PfFT1 and 2 (Folate Transporter;
Salcedo-Sora et al., 2011), PfENT4 (Equilibrative Nucleoside Trans-
porter 4; Frame et al., 2012), PfPiT (inorganic phosphate trans-
porter; Saliba et al., 2006), PfCRT (Chloroquine Resistance
Transporter; Martin et al., 2009b) and PfFNT (Formate-Nitrite
Transporter; Marchetti et al., 2015). If PfATP4 is, as has been
postulated, the parasite Naþ-ATPase, then expression of PfATP4 in
Xenopus oocytes may give rise to an increase in Naþ-ATPase activity
in the membrane fraction (under conditions in which the endog-
enous Naþ-ATPase activity of the oocyte is inhibited by the cardiac
glycoside ouabain).
An alternative to expression in X. laevis is expression in the
yeast, Saccharomyces cerevisiae, which has also been used to char-
acterise a number of malaria parasite transport proteins (e.g. the
Plasmodium Ca2þ/Hþ exchanger (Salcedo-Sora et al., 2012; Guttery
et al., 2013), the Sarcoplasmic/Endoplasmic Reticulum Ca2þ pump
PfATP6 (Pulcini et al., 2013), PfCRT (Baro et al., 2011), PfMDR1
(Amoah et al., 2007) and PfFNT (Wu et al., 2015)). A mutant Naþ-
sensitive strain of S. cerevisiae (B31) has been used previously to
study ENA-type Naþ-ATPases (Lunde et al., 2007) and this may well
serve as a suitable strain for the functional expression of PfATP4.
Expression of the Physcomitrella patens ENA-type Naþ-ATPase in
B31 yeast conferred resistance to a high extracellular [Naþ] in
complementation assays (Lunde et al., 2007). B31 yeast expressing
PfATP4 could be assayed for Naþ-dependent ATPase activity and/or
used in complementation assays in which the yeast are grown
under high-[Naþ] conditions (as in (Lunde et al., 2007)) to assess
whether PfATP4 confers an increased Naþ tolerance on the mutant
B31 strain. There has been one reported case of an ENA-type Naþ-
ATPase (from Trypanosoma, TcENA) failing to express in the B31
yeast system (Iizumi et al., 2006); it remains to be seen whether
expression of PfATP4 in this system is feasible.
The development of such heterologous expression systems for
PfATP4would allow an investigation of the nature of the interaction
of the different PfATP4-associated compound classes with PfATP4
and an analysis of the functional signiﬁcance of the various
resistance-associated mutations that have been reported to date. It
will also pave the way for the development of high throughput
assays that could be used for testing and reﬁning antimalarial
compounds with this mechanism of action.
8. Final perspectives
Historically, parasites have developed resistance to all of the
antimalarial drugs used in the ﬁeld, including the ‘wonder-drug’
chloroquine (Wellems and Plowe, 2001). The current frontline
antimalarial, artemisinin, is used throughout the developing world;
however control of the parasite in Southeast Asia is now under
signiﬁcant threat, with evidence from multiple sites that artemi-
sinin is taking longer to clear parasite infections than was previ-
ously the case (Dondorp et al., 2009, 2011; Ashley et al., 2014).
Maintaining a constant arsenal of new antimalarials is critical to
our ﬁght against the disease. PfATP4 has been identiﬁed as a target
for antimalarial drug development, and the fact that multiple high
throughput screens with asexual blood-stage parasites have
converged upon this protein is consistent with PfATP4 being
essential, inhibitable, and pharmacologically accessible. The data
are also consistent with PfATP4 being essential for the survival of
sexual-stage gametocytes. As noted above, parasites showing some
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associated antimalarials have been generated in laboratory
(in vitro) studies. Resistancewas slower to develop in vivo (Jimenez-
Diaz et al., 2014), perhaps because resistance-associated mutations
result in a ﬁtness cost. Parasites are cleared rapidly in mouse in vivo
models as well as in preliminary human trials; this may help to
counter the development of resistance in the clinical setting. The
ability to monitor PfATP4 resistance in the ﬁeld, and to distinguish
between genetic drift and relevant mutations, will undoubtedly aid
in making decisions relating to drug control.
Although a lack of understanding the mechanism of action of a
particular drug candidate does not preclude drug development,
insights into PfATP4 function, and into the nature of the interaction
of the PfATP4-associated drugs with the protein will provide a
rational basis for the design and reﬁnement of compounds of this
class, as well as facilitating an understanding of mechanisms of
resistance.
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